Latest stories
Data handling is a key but often overlooked part of governance
Governance
This first in a three-part series on topics of data governance discusses handling - which gains in importance as the reams of data generated, gathered, and analyzed rise. Prof Todd Kelsey of Benedictine University researches applied AI and its emerging business/governance models.
Todd Kelsey  |  Aug 23 , 2023
Pharma firms must abide by 10 articles to avoid foundering in a sea of data
Generic
Pharma firms shell out treasure on data and analytics but few chart sound data courses. Ganes Kesari, entrepreneur, AI thought leader, author, adjunct professor, and founder of data-science advisor Innovation Titan, spins a salty analogy to steer those so adrift into safe havens.
Ganes Kesari  |  Aug 22 , 2023
How transformational will transformer AI systems be? Jeremy Kahn weighs in
People
Tech grows by leaps and bounds and the computing punch USD1,000 can buy is rising exponentially but product and services improvements are coming only in fits and starts. Jeremy Kahn, senior writer at Fortune Magazine, sits down with The Yuan’s Calum Chace in this free-range chat.
Calum Chace  |  Aug 21 , 2023
The Hollywood writers’ AI struggle is in truth everyone’s fight
Emerging markets
Hollywood writers are currently staging a strike in protest at the disruptive way AI is being used, mostly because it threatens to upend their livelihoods. However, a closer look reveals that this issue has implications far beyond the movie and entertainment industry.
2023 BIO-Europe Spring event shows off latest developments in biotech and pharma
Emerging markets
Exciting achievements in drug development, biotech, and pharma were showcased at the 2023 BIO-Europe Spring event, which ran live in Basel, Switzerland, from March 20-22 after being held online for the past three years. Biochemist and The Yuan contributor Oladimeji Ewumi reports.
Oladimeji Ewumi  |  Aug 17 , 2023
(Bio)pharmas must advance more inclusive social agendas to build trust
Generic
(Bio)pharma firms are well positioned to ensure equal access to treatment by fostering patient trust via equity-focused drug discovery, clinical trials, commercial strategy, and healthcare ecosystem enablement, argue four healthcare executives with global management firm Kearney.
Inclusion, accessibility are indispensable for healthtech’s success
Domain knowledge
Healthtech is now more than a fad. Apps and wearables are just the start: Healthtech can potentially improve health for a huge range of people, but equal access is key, says Marketing and Commercialization Prof Marzena Nieroda of the UCL Global Business School for Health, London.
Marzena Nieroda  |  Aug 15 , 2023
Artificial neural networks are growing increasingly powerful
Brain science
ANNs decode neural activity and advance brain-computer interfaces and will soon be capable of much more - the reason medical professionals are so rosy about future personalized medicine and rare disease treatment, says software engineer and entrepreneur Mahmut Martin Yüksel, MD.
Mahmut Martin Yüksel  |  Aug 14 , 2023
AI development pause risks throwing the baby out with the bathwater
Generic
The public debate over AI constantly changes in response to AI’s own shifts. Recent advances in GAI and LLMs have prompted calls for a timeout in AI development. Prof Ricardo Vinuesa of Sweden’s KTH Royal Institute of Technology argues such a moratorium would be disastrous.
Ricardo Vinuesa  |  Aug 11 , 2023
Enterprise AI workplace ethical frameworks must be empowered, normalized
Cognition
The AI landscape is ever in flux, presenting opportunities for companies but even more risk. A thorough ethical framework is thus vital to keep up with changes and implement new tech more safely and effectively, says Sam Houston State University Entrepreneurship Prof Kyle Scott.
Kyle Scott  |  Aug 10 , 2023
Community More+
Janna Lipenkova
Janna Lipenkova
Janna Lipenkova is a computational linguist who speaks seven languages. She heads two companies, Anacode and Equintel, that use AI to deliver cutting-edge business intelligence and guide clients towards smarter decisions, strategy, and execution.
Philip M. Parker
Philip M. Parker
Philip M. Parker is Professor of Marketing at INSEAD and the INSEAD Chaired Professor of Management Science.His research explores why existing theories governing macroeconomic growth and firm level competition yield unreliable forecasts of actual market outcomes. He introduced the idea that physical sciences should be directly integrated into macroeconomic studies.
Ganes Kesari
Ganes Kesari
Ganes Kesari is an entrepreneur, AI thought leader, author, adjunct professor, and TEDx speaker. He is the founder of Innovation Titan, a data-science thought leadership and advisory firm. He advises executives on data-driven leadership and helps organizations adopt a culture of data for decision-making.
Johannes Walter
Johannes Walter
Johannes Walter is head of department and scientific director of digitalization and digital association development at Diakonie Baden as well as associate professor at IU International University of Applied Sciences. His research focuses on AI in healthcare and digital transformation in the social and healthcare sector.
Nikolaj van Omme
Nikolaj van Omme
Nikolaj van Omme is chief executive officer of Funartech, an AI startup that provides creative solutions to complex industrial problems by combining machine learning and applied mathematics. He is a strong proponent of hybrid methods and approaches, in particular the hybridization of machine learning and operations research.
Shanen Boettcher
Shanen Boettcher
Shanen Boettcher is a former General Manager of Microsoft’s Startup Business Group, which oversees the innovation of Microsoft’s core businesses. He also holds a PhD in human-machine communication and AI from the University of St Andrews, and has experience operationalizing strategy, developing global award-winning products, building tools and guidance for high-tech startups at Responsible Innovation Labs, and working as a product strategist for AI21 Labs, a leading artificial intelligence and large language model startup.
Austin Lentsch
Austin Lentsch
Austin Lentsch is a policy fellow at MIT’s Blueprint Labs.
Tonny Huang
Tonny Huang
Manager at Kearney.
Betty Pio
Betty Pio
Partner at Kearney.
Keena Patel-Moran
Keena Patel-Moran
Partner at Kearney.